APA (7th ed.) Citation

BP, E., JM, R., KL, B., E, L., F, G., A, K., . . . I, S. (2023). Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 76(4), 573. https://doi.org/10.1093/cid/ciac663

Chicago Style (17th ed.) Citation

BP, Epling, et al. "Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 76, no. 4 (2023): 573. https://doi.org/10.1093/cid/ciac663.

MLA (9th ed.) Citation

BP, Epling, et al. "Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, vol. 76, no. 4, 2023, p. 573, https://doi.org/10.1093/cid/ciac663.